Commentary|Podcasts|March 31, 2025

Embarking on the CAR-T Journey

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.

In this exclusive PC Podcast interview, Renier Brentjens, MD, PhD, deputy director and chair of medicine at the Roswell Park Comprehensive Cancer Center, discusses:

  • How he has seen the field evolve since its inception, and what excites him most about its future
  • How the Roswell Park expansion helps improve patient access to CAR T-cell therapy
  • The key safety concerns associated with CAR T-cell therapy, along with how Roswell Park aims to mitigate potential risks
  • How Roswell Park is working to make CAR T-cell therapy more widely available
  • The steps needed to be taken at the regulatory and healthcare policy levels in order to support the broader adoption of CAR T-cell therapy

The latest episode of The Pharmaceutical Commerce Podcast is available directly on Audioboom, Spotify, or iHeart.


Related to this article

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.